Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review

Table 3 Therapeutic schedule of clinical trials considered in meta-analysis

	Disease stage	Treatment arm	Control arm	Duration
Eslami	Severe	35 patients: SOC (lopinavir/ritonavir + hydroxychloroquine) + Sof/dac started 24-48 h later (after PCR and TC confirmation of COVID-19)	27 patients: SOC (lopinavir/ritonavir + hydroxychloroquine) + ribavirin	14 d
Kasgari	Moderate	24 patients: Sof/dac + ribavirin	24 patients: Lopinavir/ritonavir + hydroxychloroquine ± Ribavirin	6 d?
Sadeghi	severe	33 patients: Sof/dac + lopinavir/ritonavir	33 patients: Lopinavir/ritonavir	14 d

SOC: Standard of care; COVID-19: Coronavirus disease 2019.